Article
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Annals of hematology - 1 Aug 2018
Paludo Jonas, Abeykoon Jithma P, Shreders Amanda, Ansell Stephen M, Kumar Shaji, Ailawadhi Sikander, King Rebecca L, Koehler Amber B, Reeder Craig B, Buadi Francis K, Dispenzieri Angela, Lacy Martha Q, Dingli David, Witzig Thomas E, Go Ronald S, Gonsalves Wilson I, Kourelis Taxiarchis, Warsame Rahma, Leung Nelson, Habermann Thomas M, Hayman Suzanne, Lin Yi, Kyle Robert A, Rajkumar S Vincent, Gertz Morie A, Kapoor Prashant
Abstract excerpt
The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients' MYD88L265P mutation status. Of 160...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.